Skip to main content

Advertisement

Table 1 Baseline characteristics in total and sub-group patients

From: Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis

Characteristics Total Insulin-naïve group* Insulin non-naïve group
N 4219 3732 487
Male Missing data 1 1 0
n (%) 2485 (58.9) 2237 (59.9) 248 (50.9)
Age (years) Missing data 8 8 0
Mean ± SD 62.8 ± 12.1 62.6 ± 12.1 64.0 ± 12.1
Weight (kg) Mean ± SD 61.7 ± 11.6 61.8 ± 11.7 61.0 ± 11.5
BMI (kg/m2) Mean ± SD 23.8 ± 3.3 23.7 ± 3.3 24.0 ± 3.3
Duration of diabetes, years, n (%) Missing data 241 (5.7) 221 (5.9) 20 (4.1)
<1 50 (1.2) 46 (1.2) 4 0.8)
≥1, <5 466 (11.0) 436 (11.7) 30 (6.2)
≥5 3462 (82.1) 3029 (81.2) 433 (88.9)
OADs prescribed before study, n (%) 1 975 (23.1) 757 (20.3) 218 (44.8)
2 1719 (40.7) 1537 (41.2) 182 (37.4)
3 1189 (28.2) 1114 (29.8) 75 (15.4)
≥4 336 (8.0) 324 (8.7) 12 (2.5)
Types of OADs prescribed before study, n (%) BG 1991 (47.2) 1782 (47.7) 209 (42.9)
SU 3587 (85.0) 3316 (88.9) 271 (55.6)
Glinides 312 (7.4) 269 (7.2) 43 (8.8)
α-GI 1971 (46.7) 1717 (46.0) 254 (52.2)
TZD 1360 (32.2) 1287 (34.5) 73 (15.0)
Diabetic complications Neuropathy 1083 (25.7) 933 (25.0) 150 (30.8)
Retinopathy 1148 (27.2) 971 (26.0) 177 (36.3)
Nephropathy 1121 (26.6) 953 (25.5) 168 (34.5)
eGFR (mL/min/1.73 m2) Missing data 997 (23.6) 892 (23.9) 105 (21.6)
≥90 1030 (24.4) 933 (25.0) 97 (19.9)
≥60, <90 1558 (36.9) 1375 (36.8) 183 (37.6)
<60 634 (15.0) 532 (14.3) 102 (20.9)
  1. Note:
  2. *Insulin-naïve group: patients having been treated with OADs (n = 3732).
  3. Insulin non-naïve group: patients treated with OADs + insulin other than insulin glargine, and switching to OADs + insulin glargine (n = 487).
  4. Abbreviations: α-GI alpha-glucosidase inhibitors, BG biguanide, BMI body mass index, eGFR estimated glomerular filtration rate, OADs oral antidiabetic drugs, SD standard deviation, SU sulfonylurea, TZD, thiazolidinedione.